Funding
Nordisk
The trial was supported by two Novo Nordisk Foundation grants (NNF15SA0018346 and Excellence Grant NNF16OC0019968) and Helsefonden, all in Denmark. Cambridge Weight Plan supplied diet-replacement products. Novo Nordisk, Denmark, supplied Saxenda and placebo pens. Supporting partners did not influence or participate in trial execution, data collection or analysis, interpretation or writing, or communication of the study results.